Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20094 in overweight or obese adults
CTR20233123Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of olatorepatide in Overweight, obesity, sponsored by Hengrui Therapeutics. Started Oct 2023; status: completed.
02
Drugs
olatorepatide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20233123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233123.